Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment included in reporting. The company focuses on the development, manufacture, and marketing of pharmaceutical products for human and animal health.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2005 | Q1 2004 |
|---|---|---|
| Net Sales | $3,497.4 | $3,376.9 |
| Gross Margin | 75.4% of sales | 77.7% of sales |
| Net Income | $736.6 | $400.4 |
| Earnings Per Share (Diluted) | $0.68 | $0.37 |
| Cash Flow from Operations | $804.8 | $577.0 |
| Cash and Cash Equivalents | $5,607.7 | $2,410.4 |
| Total Debt | $4,590.1 | $6,512.5 |
Note: Total debt calculated as Short-term borrowings ($233.1M) + Long-term debt ($4,357.0M) for Q1 2005. Q1 2004 debt figures are not explicitly totaled in the text but short-term borrowings were $2,020.6M and long-term debt was $4,491.9M.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4% year-over-year. Management estimates sales would have grown 7% absent a $130 million reduction in U.S. wholesaler inventory levels due to restructured arrangements.
- Profitability Surge: Net income increased 84% to $736.6 million. This significant jump is largely attributable to a $362.3 million charge for acquired in-process research and development (IPR&D) in Q1 2004 related to the Applied Molecular Evolution acquisition, which did not recur in 2005.
- Accounting Change: The company adopted SFAS 123(R) effective January 1, 2005, requiring the expensing of stock-based compensation. This reduced Q1 2005 net income by $61.6 million compared to prior accounting methods.
- Debt Reduction: Total debt decreased by approximately $1.92 billion from December 31, 2004, primarily due to the repayment of commercial paper using available U.S. funds.
- Product Performance:
- Zyprexa: Sales declined 5% worldwide (17% in the U.S.) due to competitive pressures and inventory destocking.
- Cymbalta & Alimta: Strong growth driven by new launches and approvals.
- Diabetes Care: Sales increased 6% worldwide.
Guidance, Outlook, and Risks
Financial Expectations for 2005
- Full Year EPS: Expected to be in the range of $2.80 to $2.90 per share.
- Q2 2005 EPS: Expected to be $0.65 to $0.68 per share.
- Sales Growth: Expected to grow 8% to 10% for the full year, with acceleration in the second half.
- Margins: Gross margins expected to decline by 50 to 75 basis points.
- Tax Rate: Effective income tax rate expected to be approximately 22%.
Management Commentary and Unusual Items
- Wholesaler Restructuring: New arrangements with U.S. wholesalers are expected to reduce speculative buying but caused temporary inventory reductions impacting Q1 sales.
- Repatriation: The company commenced repatriation of approximately $8.00 billion in incentive dividends under the American Jobs Creation Act of 2004.
- Share Repurchases: No shares were repurchased under the $3.0 billion program in Q1 2005; none are expected for the remainder of the year.
Risks and Contingencies
- Zyprexa Litigation:
- Patent: On April 14, 2005, a U.S. District Court upheld Lilly's 2011 patent against generic challenges. Appeals are anticipated.
- Product Liability: Approximately 190 cases involving 540 claimants allege Zyprexa caused diabetes. Over 3,800 additional claims are under tolling agreements. An unfavorable outcome could have a material adverse impact.
- Government Investigations:
- Marketing Practices: A civil investigation by the U.S. Attorney for the Eastern District of Pennsylvania regarding marketing of Zyprexa, Prozac, and Prozac Weekly is ongoing. Potential outcomes include fines or penalties.
- Evista Patent: Litigation with Barr Laboratories regarding Evista patents is in discovery; trial date postponed.
- Other Litigation: Ongoing suits regarding DES, thimerosal, and Medicaid reimbursement pricing in New York and Alabama.
Investor Verification Checklist
- Wholesaler Inventory Impact: Verify the extent of sales suppression due to wholesaler destocking and the timeline for inventory normalization.
- Zyprexa Legal Exposure: Monitor the status of appeals regarding the Zyprexa patent and the volume of new product liability filings.
- Stock Compensation Expense: Assess the ongoing impact of SFAS 123(R) adoption on future earnings per share.
- New Product Launches: Track the commercial uptake of Cymbalta, Alimta, and the upcoming launch of Byetta (exenatide).
- Debt Strategy: Confirm the company's plan to incrementally increase debt by approximately $1 billion during the remainder of 2005.